JiangSu WuZhong Pharmaceutical Development announced that its subsidiary Suzhou Pharmaceutical Factory in the national centralized Pharmaceutical procurement has a proposed winning bid price of 3.58 yuan per vial for hydrochloride dobutamine injection and 7.47 yuan per vial for palivizumab injection. The procurement period for the two products extends until December 31, 2027, supplying provinces and cities such as Fujian, Anhui, Jilin, Hubei, Peking, and Inner Mongolia. This winning bid will help expand the sales of related products, increase market share and brand influence, and have a positive impact on the company's future Operation performance.